Could you please produce some kind of detailed, evidence-based critique of BD1's intellectual property? Since the SubB2M technology is undoubtedly the flagship product of this company, let's start with that.
Obviously, I can't speak for everyone, but I would be very interested to hear your thoughts on it.
Up until this point, you have done little more than highlight that you are not worth listening to, so this is your time to shine. Short term share price movements on the Australian Stock Exchange are not an accurate measure of determining whether a biotechnology product is good or bad, or whether a product has a genuine place in a commercial market.
I am still hearing music - and getting louder, page-207
-
- There are more pages in this discussion • 46 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IIQ (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
48.0¢ |
Change
-0.020(4.00%) |
Mkt cap ! $53.53M | |||
| Open | High | Low | Value | Volume |
| 48.0¢ | 50.0¢ | 47.5¢ | $64.20K | 132.4K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 41187 | 47.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 48.5¢ | 10000 | 2 |
View Market Depth
| Last trade - 15.59pm 01/10/2024 (20 minute delay) ? |
| IIQ (ASX) Chart |